Evidence map›Paper›PMID 42136962›Full record

ArticleHuman mutation2026

Integrative Single-Cell and Spatial Transcriptomics Reveal Organelle Stress-Associated Heterogeneity and Immune Microenvironment Remodeling in Lung Adenocarcinoma.

Xiaoyan Chang, Meifeng Li, Chenghao Wang, Xiang Zhou, Yupeng Zhao, Simiao Chen, Linyou Zhang

Abstract read
In one paragraph

Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoyan ChangDepartment of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn.
Meifeng LiDepartment of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn.
Chenghao WangDepartment of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn.
Xiang ZhouDepartment of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn.
Yupeng ZhaoDepartment of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn.
Simiao ChenDepartment of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn.
Linyou ZhangDepartment of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn.ORCID https://orcid.org/0000-0002-9946-4213

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung adenocarcinoma (LUAD) exhibits marked heterogeneity. Organelle stress-adaptive programs that tumor cells develop under hypoxia, nutrient limitation, and proteostasis pressure may drive functional reprogramming of tumor biology, remodel the immune microenvironment, and ultimately influence the benefits of immunotherapy. Therefore, it is necessary to systematically characterize the coordinated changes across organelle stress-related pathways in LUAD, establish a subtyping and prognostic stratification framework, and identify key molecules as well as potential cell-cell communication axes. Methods: Transcriptomic profiles and clinical follow-up data from The Cancer Genome Atlas LUAD (TCGA-LUAD) cohort and public cohorts were collected. Pathway activities were quantified using organelle stress-related gene sets, and core stress programs associated with overall survival (OS) and progression-free survival (PFS) were screened by Cox regression and Kaplan-Meier analyses. Nonnegative matrix factorization (NMF) was used for unsupervised subtyping and stability evaluation. Functional enrichment, genomic features, and immune landscapes were compared between subtypes, and potential benefit from immune checkpoint blockade (ICB) was inferred using tumor immune dysfunction and exclusion (TIDE) and immunophenoscore (IPS). Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) were integrated to characterize malignant cell states, spatial niches, and cell-cell communication networks. In LUAD cell lines, the candidate gene was silenced by small interfering RNA (siRNA), and phenotypic assays were performed to validate its effects. Results: The organelle stress activity-based system robustly classified LUAD into two biologically distinct subtypes (the mitochondrial-ribosome biogenesis, MRB, subtype and the lysosomal catabolism, LC, subtype), which showed systematic differences in prognosis and functional programs. The MRB subtype exhibited enhanced stress and metabolic adaptation accompanied by immune exclusion features, whereas the LC subtype showed a relatively immune-active tumor microenvironment. Immunotherapy-related analyses suggested divergent trends in potential ICB benefit between the two subtypes. Multiscale evidence highlighted SLC16A14 (MCT14) as a key node linking stress heterogeneity to malignant progression. At the single-cell level, SLC16A14 was mainly expressed in malignant cells, and communication analyses suggested that CALCR-related signaling may mediate tumor-endothelial interactions and contribute to an immune-excluded microenvironment. In vitro, SLC16A14 silencing suppressed tumor cell proliferation, invasion, and migration, supporting its role as a key molecule connecting stress adaptation and tumor progression. Conclusion: We established an organelle stress program-based subtyping and prognostic framework for LUAD, revealed the coupling between stress adaptation and TME remodeling, and proposed SLC16A14 and its associated communication network as potential intervention targets, providing multiomics evidence for interpreting LUAD heterogeneity and for stratifying immunotherapy and combination strategies.

Indexed as

Adenocarcinoma of LungLung NeoplasmsOrganellesStress, PhysiologicalTumor MicroenvironmentBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisSpatial TranscriptomicsTranscriptomeBiomarkers, Tumorimmunotherapymultiomicsorganelle stressSLC16A14tumor microenvironment

Identifiers

PMID42136962
PMCPMC13168938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.